leisure time -WSS

leisure time

author：focus 2025-09-14 21:56:45 - browse：32415

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Sanofi seeks simpler, safer CRISPR sickle cell cure

WSS

Listen: Wegovy in the brain & pivotal Alzheimer's data

Humana sues Biden admin over Medicare Advantage audit rule

Google and Epic fight stronger regulation of AI in health care

NIH nominee Bertagnolli will get October confirmation hearing

A public scorecard can help hold safety

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

leisure time

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The (many) problems with a new study criticizing cancer screening

Malaria cases in Florida and Texas: Here’s what you need to know

How dance can help nurses traumatized by Covid

23andMe had bad news about my health. I wish a person had delivered it

Biden tests positive for Covid

Activists slam private health insurers over coverage restrictions

As digital health tech proliferates, a new institute aims to cut through hype

Medical leaders decry Supreme Court decision on affirmative action

House transparency, PBM reform bill gains bipartisan support

knowledge

STAT Virtual Event: The State of Biosimilars: What to Watch

Custom gene therapy hints at new path for rare disease treatments

Weighted lottery helped low

Biden tests positive for Covid

How Medicaid coverage policies for immigrants impact new moms

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

entertainment

focus

leisure time

focus